Sun Pharma's innovation arm strives to complete Covid-hit clinical trials
SPARC focuses on discovery and research of novel drugs prioritised in three therapeutic areas i.e. oncology, neurology and immunology. According to the company, during FY22, SPARC raised $148 million to complete the ongoing clinical studies.
Source: businesstoday.in